Citius Pharmaceuticals (CTXR) Financials

Citius Pharmaceuticals logo
$0.52 -0.01 (-1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 0.00 (-0.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Citius Pharmaceuticals

Annual Income Statements for Citius Pharmaceuticals

This table shows Citius Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders
-2.90 -8.30 -10 -13 -16 -18 -25 -34 -34 -40 -37
Consolidated Net Income / (Loss)
-2.90 -8.30 -10 -13 -16 -18 -23 -34 -33 -39 -40
Net Income / (Loss) Continuing Operations
-2.90 -8.30 -10 -13 -16 -18 -23 -34 -33 -39 -40
Total Pre-Tax Income
-2.90 -8.30 10 13 -16 -18 -23 -33 -32 -39 -39
Total Operating Income
-3.23 -7.45 -9.99 -14 -16 -18 -24 -33 -37 -42 -39
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
3.23 7.45 9.99 14 16 18 24 33 37 42 39
Selling, General & Admin Expense
1.43 4.52 6.06 6.45 6.29 8.90 9.84 12 15 18 19
Research & Development Expense
1.80 2.93 2.94 6.56 8.60 8.81 12 18 15 12 9.16
Other Special Charges / (Income)
- - 0.99 0.78 0.72 - 1.45 3.91 6.62 12 11
Total Other Income / (Expense), net
0.33 -0.85 -0.40 1.25 0.04 0.16 0.48 0.25 4.77 3.15 -0.16
Interest Expense
0.01 0.01 0.85 -0.43 0.02 0.02 -0.16 - -3.59 0.00 0.27
Interest & Investment Income
0.00 0.00 0.00 0.00 0.05 0.07 0.26 0.25 1.18 0.76 0.11
Other Income / (Expense), net
0.33 -0.84 0.45 0.82 0.00 0.11 0.06 0.00 - 2.39 0.00
Income Tax Expense
0.00 0.00 0.00 0.00 0.00 - 0.00 0.58 0.58 0.58 1.06
Preferred Stock Dividends Declared
- - - - - 0.00 1.45 - 1.15 1.05 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
- - - - - - - - 0.00 -0.29 -2.31
Basic Earnings per Share
($1.37) ($2.29) ($1.89) ($1.17) ($0.77) ($0.45) ($0.23) - ($5.57) ($5.97) ($3.38)
Weighted Average Basic Shares Outstanding
2.12M 3.62M 5.48M 10.73M 20.16M 39.17M 108.60M 146.08M 6.05M 6.73M 11.07M
Diluted Earnings per Share
($1.37) ($2.29) ($1.89) ($1.17) ($0.77) ($0.45) - - ($5.57) ($5.97) ($3.38)
Weighted Average Diluted Shares Outstanding
2.12M 3.62M 5.48M 10.73M 20.16M 39.17M 108.60M 146.21M 6.05M 6.73M 11.07M

Quarterly Income Statements for Citius Pharmaceuticals

This table shows Citius Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.23 -8.54 -11 -12 -9.77 -11 -8.79 -7.96 -8.22 -21 -8.86
Consolidated Net Income / (Loss)
-9.23 -8.54 -11 -11 -10 -12 -9.20 -8.74 -9.39 -28 -12
Net Income / (Loss) Continuing Operations
-9.23 -8.54 -11 -11 -10 -12 -9.20 -8.74 -9.39 -28 -12
Total Pre-Tax Income
-9.09 -8.40 -10 -11 -10 -11 -8.94 -8.48 -9.13 -28 -12
Total Operating Income
-9.34 -11 -11 -11 -10 -11 -8.79 -8.44 -9.02 -32 -12
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.15 1.34 1.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.94 1.67 1.49
Operating Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 3.94 1.67 1.49
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.79 0.33 0.49
Operating Cost of Revenue
- - - - 0.00 0.00 0.00 - 0.79 0.33 0.49
Total Operating Expenses
9.34 11 11 11 10 11 8.79 8.44 12 34 13
Selling, General & Admin Expense
3.66 4.29 4.81 5.49 5.39 4.79 4.45 3.91 5.72 26 6.15
Research & Development Expense
2.62 3.61 2.76 2.91 2.13 3.77 1.62 1.64 2.17 3.35 2.77
Other Special Charges / (Income)
3.06 3.08 3.06 2.64 2.52 2.70 2.72 2.89 4.28 3.79 3.81
Total Other Income / (Expense), net
0.25 2.57 0.20 0.12 0.02 0.01 -0.15 -0.04 -0.11 3.85 -0.29
Interest Expense
- - 0.00 - 0.00 0.00 0.17 - 0.16 0.03 0.23
Interest & Investment Income
0.25 0.18 0.20 0.12 0.02 0.01 0.02 0.05 0.05 3.89 0.12
Other Income / (Expense), net
- 2.39 0.00 - - - 0.00 - - - -0.18
Income Tax Expense
0.14 0.14 0.14 0.14 0.26 0.26 0.26 0.26 0.26 -0.23 -0.11
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 0.00 0.00 - -0.51 -0.60 -0.41 -0.78 -1.17 -6.88 -3.06
Basic Earnings per Share
($1.45) ($1.34) ($1.57) ($1.71) ($1.30) ($1.27) ($0.80) ($0.72) ($0.38) ($0.95) ($0.34)
Weighted Average Basic Shares Outstanding
6.36M 6.36M 6.95M 6.73M 7.49M 8.58M 11.01M 11.07M 21.50M 22.38M 26.17M
Diluted Earnings per Share
($1.45) ($1.34) ($1.57) ($1.71) ($1.30) ($1.27) ($0.80) ($0.72) ($0.38) ($0.95) ($0.34)
Weighted Average Diluted Shares Outstanding
6.36M 6.36M 6.95M 6.73M 7.49M 8.58M 11.01M 11.07M 21.50M 22.38M 26.17M

Annual Cash Flow Statements for Citius Pharmaceuticals

This table details how cash moves in and out of Citius Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents
-0.88 -0.38 2.91 5.98 -1.29 5.97 56 -28 -15 -23 1.00
Net Cash From Operating Activities
-2.39 -5.90 -7.97 -11 -12 -17 -24 -28 -29 -28 -27
Net Cash From Continuing Operating Activities
-2.39 -5.90 -7.97 -11 -12 -17 -24 -28 -29 -28 -27
Net Income / (Loss) Continuing Operations
-2.90 -8.30 -10 -13 -16 -18 -23 -34 -33 -39 -40
Consolidated Net Income / (Loss)
-2.90 -8.30 -10 -13 -16 -18 -23 -34 -33 -39 -40
Depreciation Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense
- - - - 0.00 0.15 0.16 0.18 0.19 0.21 0.21
Non-Cash Adjustments To Reconcile Net Income
0.17 1.68 2.30 0.68 0.93 1.21 1.36 4.28 6.72 12 11
Changes in Operating Assets and Liabilities, net
0.35 0.71 0.12 0.54 2.20 -0.74 -2.72 0.82 -3.43 -1.11 2.11
Net Cash From Investing Activities
0.00 0.26 -0.00 0.00 0.00 -0.00 -40 0.00 0.00 -5.00 -5.75
Net Cash From Continuing Investing Activities
0.00 0.26 -0.00 0.00 0.00 -0.00 -40 0.00 0.00 -5.00 -5.75
Acquisitions
- - - - - 0.00 - - - -5.00 -5.75
Net Cash From Financing Activities
1.51 5.26 11 17 11 23 120 0.00 14 9.97 33
Net Cash From Continuing Financing Activities
1.51 5.26 11 17 11 23 120 0.00 14 9.97 33
Repayment of Debt
0.00 -0.66 - - - - -0.17 - - 0.00 -0.30
Payment of Dividends
- - - - - - - - 0.00 -3.83 0.00
Issuance of Debt
0.00 0.50 4.21 0.00 0.00 0.16 - - - 0.00 1.30
Issuance of Common Equity
1.51 5.43 6.67 0.00 4.83 6.88 121 0.00 14 14 32
Cash Interest Paid
0.00 0.00 0.00 0.00 - - - - - 0.00 0.19

Quarterly Cash Flow Statements for Citius Pharmaceuticals

This table details how cash moves in and out of Citius Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents
-6.14 -7.79 5.35 -15 -2.15 -1.07 6.06 -1.84 3.47 -3.13 12
Net Cash From Operating Activities
-6.14 -7.79 -8.37 -5.91 -4.73 -4.54 -5.41 -12 -13 -1.30 -8.68
Net Cash From Continuing Operating Activities
-6.14 -7.79 -8.37 -5.91 -4.73 -4.54 -5.41 -12 -13 -1.30 -8.68
Net Income / (Loss) Continuing Operations
-9.23 -8.54 -11 -11 -10 -12 -9.20 -8.74 -9.39 -28 -12
Consolidated Net Income / (Loss)
-9.23 -8.54 -11 -11 -10 -12 -9.20 -8.74 -9.39 -28 -12
Amortization Expense
0.05 0.05 0.05 0.05 0.05 0.06 0.04 0.06 0.56 1.76 1.94
Non-Cash Adjustments To Reconcile Net Income
3.13 3.18 3.17 2.64 2.52 2.70 2.72 2.92 0.41 6.76 4.89
Changes in Operating Assets and Liabilities, net
-0.09 -2.47 -1.02 2.47 2.98 4.21 1.04 -6.12 -4.58 18 -3.59
Net Cash From Investing Activities
0.00 - - -5.00 0.00 - - -5.75 -4.40 -0.60 -2.00
Net Cash From Continuing Investing Activities
0.00 - - -5.00 0.00 - - -5.75 -4.40 -0.60 -2.00
Net Cash From Financing Activities
0.00 - 14 -3.75 2.57 3.47 11 16 21 -1.23 23
Net Cash From Continuing Financing Activities
0.00 - 14 -3.75 2.57 3.47 11 16 21 -1.23 23
Repayment of Debt
- - - - - - - - - - -0.72
Issuance of Common Equity
0.00 - 14 0.08 2.57 3.47 10 16 21 -0.06 4.45
Other Financing Activities, net
- - - - - - - - - - 9.73
Cash Interest Paid
- - - - 0.00 - - - 0.01 0.09 0.20

Annual Balance Sheets for Citius Pharmaceuticals

This table presents Citius Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets
0.74 22 24 31 37 44 142 114 104 117 131
Total Current Assets
0.74 0.89 3.42 10 7.94 14 73 45 34 14 28
Cash & Equivalents
0.68 0.29 3.20 9.18 7.89 14 70 42 26 3.25 4.25
Accounts Receivable
- - 0.00 0.82 - - - - - - 0.00
Inventories, net
- - - - - - - - - 8.27 22
Prepaid Expenses
0.06 0.60 0.22 0.06 0.05 0.12 2.74 2.85 7.89 2.70 1.40
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.25 0.00
Total Noncurrent Assets
0.01 21 21 21 29 30 70 69 69 204 112
Goodwill
0.00 1.59 1.59 1.59 9.35 9.35 9.35 9.35 9.35 9.35 9.35
Other Noncurrent Operating Assets
0.00 19 19 19 19 20 60 60 60 195 103
Total Liabilities & Shareholders' Equity
0.74 22 24 31 37 44 142 114 104 117 131
Total Liabilities
1.38 5.18 2.47 3.18 9.59 10 9.65 11 12 43 53
Total Current Liabilities
1.38 5.18 2.47 3.18 4.61 4.10 3.98 4.53 5.78 36 45
Short-Term Debt
0.00 0.67 0.17 0.17 0.17 0.17 - - - 0.00 1.00
Accounts Payable
0.63 0.94 0.63 1.57 2.71 1.86 1.28 1.17 2.93 4.93 14
Accrued Expenses
0.01 0.96 0.56 0.18 0.25 0.16 0.62 1.41 0.48 0.02 4.19
Current Employee Benefit Liabilities
0.00 0.90 1.06 1.20 1.40 1.65 1.91 1.76 2.16 2.23 3.29
Other Current Liabilities
0.74 1.68 - - 0.00 0.16 0.18 0.20 0.22 29 23
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 4.99 6.01 5.66 6.04 6.40 6.74 8.50
Long-Term Debt
- - - - 0.00 0.16 - - - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - 4.99 4.99 4.99 5.56 6.14 6.71 7.77
Other Noncurrent Operating Liabilities
- - - - 0.00 0.86 0.68 0.48 0.26 - 0.72
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-0.64 17 22 28 27 34 133 103 91 74 78
Total Preferred & Common Equity
-0.64 17 22 28 27 34 132 103 91 70 68
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-0.64 17 22 28 27 34 132 103 91 70 68
Common Stock
8.41 34 50 68 80 104 228 233 253 271 306
Retained Earnings
-9.04 -17 -28 -40 -53 -71 -96 -130 -162 -201 -239
Noncontrolling Interest
- - - - - 0.00 0.60 0.60 0.60 4.02 9.98

Quarterly Balance Sheets for Citius Pharmaceuticals

This table presents Citius Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025 6/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Assets
97 91 97 121 121 128 140 133 142
Total Current Assets
28 22 28 18 18 25 38 32 43
Cash & Equivalents
20 13 18 1.10 0.03 6.09 7.72 4.59 17
Accounts Receivable
- - - - - - 4.05 1.08 0.69
Inventories, net
- - - 15 15 17 23 23 23
Prepaid Expenses
7.86 9.01 10 2.85 3.01 1.31 3.54 3.36 3.01
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.92 0.00 0.84 0.00 0.00
Total Noncurrent Assets
69 69 69 102 102 205 102 100 108
Goodwill
9.35 9.35 9.35 9.35 9.35 9.35 9.35 9.35 9.35
Other Noncurrent Operating Assets
60 60 60 93 93 196 0.04 0.21 99
Total Liabilities & Shareholders' Equity
97 91 97 121 121 128 140 133 142
Total Liabilities
12 11 11 52 58 60 47 63 66
Total Current Liabilities
5.58 4.17 4.15 45 50 52 38 55 52
Short-Term Debt
- - - - - 1.00 1.00 0.00 0.00
Accounts Payable
2.65 2.67 1.66 7.36 9.37 10 11 9.45 8.04
Accrued Expenses
0.28 0.15 0.55 6.24 8.78 8.52 4.69 24 26
Current Employee Benefit Liabilities
2.43 1.12 1.70 2.60 3.18 3.71 3.09 3.60 1.87
Other Current Liabilities
0.22 0.23 0.24 29 29 29 18 18 16
Total Noncurrent Liabilities
6.49 6.57 6.65 6.98 8.03 8.27 8.72 8.44 15
Long-Term Debt
- - - - - - - - 6.41
Noncurrent Deferred & Payable Income Tax Liabilities
6.28 6.43 6.57 6.98 7.24 7.51 8.04 7.80 7.70
Other Noncurrent Operating Liabilities
0.20 0.15 0.08 0.00 - 0.77 - - 0.59
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
85 80 86 69 64 68 93 69 76
Total Preferred & Common Equity
85 79 86 65 61 65 80 62 67
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
85 79 86 65 61 65 80 62 67
Common Stock
256 259 276 277 283 296 327 330 344
Retained Earnings
-171 -180 -191 -211 -222 -231 -247 -268 -277
Noncontrolling Interest
0.60 0.60 0.60 3.51 2.92 2.50 14 7.54 9.30

Annual Metrics And Ratios for Citius Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Citius Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
DEI Shares Outstanding
33,767,877.00 73,038,060.00 8,252,798.00 16,198,791.00 22,075,781.00 55,475,822.00 145,979,429.00 146,129,630.00 158,857,798.00 - 159,094,781.00
DEI Adjusted Shares Outstanding
1,350,715.00 2,921,522.00 330,112.00 647,952.00 883,031.00 2,219,033.00 5,839,177.00 5,845,185.00 6,354,312.00 - 6,363,791.00
DEI Earnings Per Adjusted Shares Outstanding
-2.15 -2.84 -31.46 -19.35 -17.62 -7.91 -4.20 -5.76 -5.30 - -5.88
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-359.09% -185.94% -15.03% -36.06% -20.27% -11.87% -33.58% -42.17% -10.26% -14.36% 2.76%
EBIT Growth
-349.13% -185.99% -15.04% -36.05% -20.26% -12.84% -33.36% -41.94% -10.25% -14.33% 2.73%
NOPAT Growth
-394.02% -130.63% -91.51% -38.08% 20.82% -13.54% -32.87% -41.58% -10.25% -14.33% 8.26%
Net Income Growth
-293.41% -185.84% -25.18% -20.72% -24.13% -12.76% -31.38% -45.92% 3.26% -21.15% -0.80%
EPS Growth
-3,325.00% -67.15% 17.47% 38.10% 34.19% 41.56% 0.00% 0.00% 0.00% -21.15% 43.38%
Operating Cash Flow Growth
-1,202.34% -147.35% -35.10% -41.99% -9.89% -36.12% -43.23% -16.95% -2.46% 2.96% 5.85%
Free Cash Flow Firm Growth
-278.86% -634.58% 49.94% -16.14% 16.23% -14.04% -348.94% 62.12% -29.49% -375.67% 77.39%
Invested Capital Growth
42.18% 1,404.84% 10.80% -0.24% 3.14% 3.75% 209.85% -1.59% 5.18% 166.57% 2.39%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-39.03% -25.35% 3.30% -3.52% 0.03% -2.49% -4.72% -7.61% -7.57% -2.26% 6.40%
EBIT Q/Q Growth
-39.03% -25.36% 3.30% -3.52% 0.03% -2.70% -4.70% -7.58% -7.54% -2.25% 6.35%
NOPAT Q/Q Growth
-36.57% -48.66% -29.81% -10.05% 30.02% -2.81% -4.73% -7.58% -7.54% -2.25% 6.35%
Net Income Q/Q Growth
-40.06% -25.42% -4.57% 1.54% -5.44% -2.76% -3.78% -9.90% -6.39% -2.96% 5.55%
EPS Q/Q Growth
-1,857.14% -8.53% 35.93% 18.18% 1.28% 16.67% 0.00% 0.00% 0.00% 0.00% 9.14%
Operating Cash Flow Q/Q Growth
-89.25% -21.94% -26.35% 7.55% -3.35% -2.73% -10.14% -2.68% -1.64% 3.05% -28.99%
Free Cash Flow Firm Q/Q Growth
-778.18% -5.65% -50.77% 6.77% 16.22% 15.12% -252.96% 64.19% -8.54% -328.36% 75.14%
Invested Capital Q/Q Growth
38.48% 2.26% 12.25% -0.98% 13.15% -1.99% 190.06% -0.93% -0.16% 153.07% 7.61%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% -100.00% -100.00% 100.00% 100.00% 100.00% 101.74% 101.80% 101.48% 102.73%
Interest Burden Percent
100.15% 100.10% -108.92% -96.65% 99.77% 99.70% 98.22% 99.25% 87.03% 92.51% 100.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
421.49% -102.85% -53.65% -50.33% -56.57% -57.70% -27.70% -28.48% -33.40% -47.63% -52.42%
Cash Return on Invested Capital (CROIC)
0.00% -138.14% -65.62% -72.58% -59.93% -66.07% -142.12% -35.89% -45.66% -115.59% -17.76%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
421.49% -102.85% -53.65% -50.33% -56.57% -57.70% -27.60% -28.34% -33.20% -46.30% -47.58%
Return on Equity Simple (ROE_SIMPLE)
456.90% -49.48% -47.32% -44.99% -57.31% -52.12% -17.44% -32.72% -35.83% -56.26% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.26 -5.21 -9.99 -14 -11 -12 -16 -23 -26 -29 -27
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-58.24% -1,859.23% -30.15% 20.98% -55.94% -48.87% -15.76% -18.46% -20.02% 27.70% 12.86%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -28.12% -39.67% -34.03%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.90 -8.29 -9.53 -13 -16 -18 -23 -33 -37 -42 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.90 -8.29 -9.53 -13 -16 -17 -23 -33 -37 -42 -38
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 1.19 0.99 0.62 1.71 2.24 1.72 1.20 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 1.28 1.05 0.94 2.37 2.41 1.89 1.33 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 1.21 0.99 0.46 2.18 3.62 2.20 1.28 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.04 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.02
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage
1.60 -0.02 -0.07 -0.24 -0.30 -0.35 -0.50 -0.47 -0.35 0.44 1.31
Leverage Ratio
-1.67 1.41 1.20 1.11 1.23 1.32 1.12 1.09 1.12 1.33 1.63
Compound Leverage Factor
-1.67 1.41 -1.30 -1.08 1.23 1.32 1.10 1.08 0.97 1.23 1.64
Debt to Total Capital
0.00% 3.86% 0.78% 0.62% 0.63% 0.99% 0.00% 0.00% 0.00% 0.00% 2.18%
Short-Term Debt to Total Capital
0.00% 3.86% 0.78% 0.62% 0.63% 0.51% 0.00% 0.00% 0.00% 0.00% 1.26%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.48% 0.00% 0.00% 0.00% 0.00% 0.91%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.45% 0.58% 0.66% 5.43% 12.59%
Common Equity to Total Capital
100.00% 96.14% 99.22% 99.38% 99.37% 99.01% 99.55% 99.42% 99.34% 94.57% 85.23%
Debt to EBITDA
0.00 -0.08 -0.02 -0.01 -0.01 -0.02 0.00 0.00 0.00 0.00 -0.05
Net Debt to EBITDA
0.00 -0.05 0.32 0.69 0.50 0.78 0.00 0.00 0.00 0.00 0.07
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 -0.02
Debt to NOPAT
0.00 -0.13 -0.02 -0.01 -0.02 -0.03 0.00 0.00 0.00 0.00 -0.06
Net Debt to NOPAT
0.00 -0.07 0.30 0.65 0.71 1.09 0.00 0.00 0.00 0.00 0.09
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 -0.03
Altman Z-Score
0.00 0.00 3.49 2.29 -2.27 0.11 17.52 7.90 2.33 0.00 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.36% 0.51% 0.62% 2.79% 9.23%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.53 0.17 1.39 3.16 1.72 3.41 18.28 9.84 5.95 0.40 0.62
Quick Ratio
0.49 0.06 1.30 3.14 1.71 3.38 17.60 9.21 4.58 0.09 0.09
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.22 -24 -12 -14 -12 -13 -59 -22 -29 -138 -31
Operating Cash Flow to CapEx
0.00% 0.00% -374,939.09% 0.00% 0.00% -924,667.29% -60.62% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-429.04 -2,628.08 -13.91 0.00 -700.16 -837.72 0.00 0.00 0.00 0.00 -116.13
Operating Cash Flow to Interest Expense
-318.06 -656.04 -9.37 0.00 -756.42 -1,080.24 0.00 0.00 0.00 0.00 -99.16
Operating Cash Flow Less CapEx to Interest Expense
-318.06 -656.04 -9.37 0.00 -756.42 -1,080.36 0.00 0.00 0.00 0.00 -99.16
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-1.31 17 19 19 20 20 63 62 65 173 177
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.96 18 1.85 -0.05 0.59 0.73 42 -1.00 3.20 108 4.13
Enterprise Value (EV)
0.00 0.00 23 19 9.00 44 227 136 83 0.00 0.00
Market Capitalization
0.00 0.00 26 28 17 58 296 177 109 0.00 0.00
Book Value per Share
($0.02) $0.23 $2.66 $1.72 $1.23 $0.61 $0.91 $0.70 $0.57 $10.42 $6.10
Tangible Book Value per Share
($0.02) $0.21 $2.47 $1.62 $0.81 $0.44 $0.84 $0.64 $0.51 $9.03 $5.26
Total Capital
-0.64 17 22 28 27 34 133 103 91 74 79
Total Debt
0.00 0.67 0.17 0.17 0.17 0.34 0.00 0.00 0.00 0.00 1.72
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.16 0.00 0.00 0.00 0.00 0.72
Net Debt
-0.68 0.38 -3.03 -9.01 -7.72 -14 -70 -42 -26 -3.25 -2.53
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 40 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.32 -3.91 -2.08 -2.14 -4.39 -3.80 -1.24 -1.68 2.11 -25 -20
Debt-free Net Working Capital (DFNWC)
-0.64 -3.62 1.13 7.05 3.51 10 69 40 29 -22 -16
Net Working Capital (NWC)
-0.64 -4.29 0.96 6.88 3.33 9.88 69 40 29 -22 -17
Net Nonoperating Expense (NNE)
0.64 3.08 0.40 -1.25 4.64 5.15 6.58 10 6.83 10 13
Net Nonoperating Obligations (NNO)
-0.68 0.34 -2.99 -8.95 -7.65 -13 -70 -42 -27 99 100
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.15 0.16 0.18 0.19 0.21 0.21
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.09) ($0.15) ($1.89) ($1.17) ($0.77) ($0.45) ($0.23) ($0.23) ($5.50) ($5.97) ($3.38)
Adjusted Weighted Average Basic Shares Outstanding
34.70M 74.11M 8.42M 17.80M 28.93M 55.58M 146.03M 146.08M 6.05M 6.73M 11.07M
Adjusted Diluted Earnings per Share
($0.09) ($0.15) ($1.89) ($1.17) ($0.77) ($0.45) ($0.23) $0.00 $0.00 ($5.97) ($3.38)
Adjusted Weighted Average Diluted Shares Outstanding
34.70M 74.11M 8.42M 17.80M 28.93M 55.58M 146.03M 146.21M 6.36M 6.73M 11.07M
Adjusted Basic & Diluted Earnings per Share
($0.09) ($0.15) ($1.89) ($1.17) ($0.77) ($0.45) ($0.23) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
31.84M 54.35M 5.48M 10.73M 20.16M 39.17M 108.60M 146.21M 6.36M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-2.26 -5.21 -6.30 -9.11 -10 -12 -15 -21 -21 -21 -19
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-386.38 -921.45 -11.21 0.00 -948.63 -1,122.98 0.00 0.00 0.00 0.00 -143.87
NOPAT to Interest Expense
-301.46 -579.78 -11.74 0.00 -664.04 -791.01 0.00 0.00 0.00 0.00 -100.71
EBIT Less CapEx to Interest Expense
-386.38 -921.45 -11.21 0.00 -948.63 -1,123.10 0.00 0.00 0.00 0.00 -143.87
NOPAT Less CapEx to Interest Expense
-301.46 -579.78 -11.74 0.00 -664.04 -791.13 0.00 0.00 0.00 0.00 -100.71
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.72% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.72% 0.00%

Quarterly Metrics And Ratios for Citius Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Citius Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding
158,857,798.00 159,094,781.00 159,094,781.00 - - 159,094,781.00 159,094,781.00 159,094,781.00 159,094,781.00 159,094,781.00 27,452,570.00
DEI Adjusted Shares Outstanding
6,354,312.00 6,363,791.00 6,363,791.00 - - 6,363,791.00 6,363,791.00 6,363,791.00 6,363,791.00 6,363,791.00 27,452,570.00
DEI Earnings Per Adjusted Shares Outstanding
-1.45 -1.34 -1.71 - - -1.72 -1.38 -1.25 -1.29 -3.34 -0.32
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-28.98% 19.81% -22.71% -9.15% -7.48% -31.35% 17.34% 23.84% 15.25% -171.62% -13.99%
EBIT Growth
-28.84% 19.68% -22.63% -9.14% -7.48% -31.21% 17.36% 23.65% 10.16% -185.90% -35.54%
NOPAT Growth
-28.84% -2.67% -22.63% -9.14% -7.48% -2.65% 17.36% 23.65% 10.16% -185.90% -33.50%
Net Income Growth
-156.88% 18.83% -24.70% -11.40% -11.38% -34.73% 12.95% 21.07% 8.63% -144.19% -29.50%
EPS Growth
0.00% 0.00% 0.00% -11.40% 10.34% 5.22% 49.04% 57.89% 70.77% 25.20% 57.50%
Operating Cash Flow Growth
-27.17% 0.85% 12.68% 13.05% 22.97% 41.70% 35.38% -100.94% -175.27% 71.36% -60.50%
Free Cash Flow Firm Growth
26.81% -58.66% -22.75% -1,026.44% -33.56% 61.03% -848.59% 91.34% -162.95% -384.94% 179.80%
Invested Capital Growth
1.31% 7.44% 5.16% 166.57% 4.36% -4.56% 140.82% 2.39% 28.91% 1.24% -54.64%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -57.73% -10.41%
EBITDA Q/Q Growth
7.79% 8.18% -24.04% -3.93% 9.20% -12.22% 21.94% 4.25% -1.04% -259.64% 67.24%
EBIT Q/Q Growth
7.74% 8.12% -23.91% -3.91% 9.15% -12.16% 21.96% 3.99% -6.90% -256.96% 63.00%
NOPAT Q/Q Growth
7.74% -17.44% 3.06% -3.91% 9.15% -12.16% 21.96% 3.99% -6.90% -256.96% 63.56%
Net Income Q/Q Growth
7.17% 7.44% -23.75% -4.77% 7.19% -11.97% 20.05% 5.00% -7.44% -199.23% 57.60%
EPS Q/Q Growth
7.17% 7.44% -23.75% 0.00% 23.98% 2.31% 37.01% 10.00% 47.22% -150.00% 64.21%
Operating Cash Flow Q/Q Growth
9.78% -26.90% -7.47% 29.34% 20.07% 3.94% -19.10% -119.75% -9.49% 90.01% -567.49%
Free Cash Flow Firm Q/Q Growth
28.24% -67.26% 12.53% -972.89% 91.49% 51.20% -2,029.09% 90.20% -158.32% 10.00% 450.38%
Invested Capital Q/Q Growth
0.12% 3.72% 1.43% 153.07% -60.81% -5.14% 155.93% 7.61% -50.66% -25.50% 14.69%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 79.99% 80.27% 67.07%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -214.55% -1,825.34% -667.45%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -228.68% -1,930.96% -785.39%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -228.68% -1,930.96% -797.41%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -238.18% -1,685.95% -797.92%
Tax Burden Percent
101.58% 101.71% 101.38% 101.32% 102.64% 102.35% 102.96% 103.12% 102.89% 99.18% 99.11%
Interest Burden Percent
97.28% 97.88% 98.07% 98.94% 99.77% 99.88% 101.73% 100.50% 101.22% 88.03% 100.97%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.13% -117.17% -32.64%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 78.16% 231.91% -40.37%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.44% -5.58% -26.98%
Return on Equity (ROE)
-40.97% -42.15% -41.49% -47.63% -52.48% -60.53% -54.70% -52.42% -11.57% -122.75% -59.62%
Cash Return on Invested Capital (CROIC)
-43.39% -49.24% -48.13% -115.59% -49.27% -41.02% -107.35% -17.76% -59.08% -64.42% 39.27%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.91% -85.31% -41.98%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.20% -74.49% -42.01%
Return on Common Equity (ROCE)
-40.71% -41.85% -41.22% -46.30% -51.08% -59.05% -53.59% -47.58% -10.36% -113.07% -54.72%
Return on Equity Simple (ROE_SIMPLE)
-45.06% -45.61% 0.00% 0.00% -61.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-6.54 -7.68 -7.44 -7.74 -7.03 -7.88 -6.15 -5.91 -6.31 -23 -8.21
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -160.07% -1,351.67% -549.77%
Net Nonoperating Expense Percent (NNEP)
-9.41% -4.16% -12.23% 9.23% -30.34% -61.51% 7.71% 2.86% -86.29% -349.08% 7.73%
Return On Investment Capital (ROIC_SIMPLE)
-7.66% -9.60% -8.63% -10.44% -10.20% -12.25% -8.97% -7.45% -6.64% -32.32% -9.98%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 20.01% 19.73% 32.93%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 145.04% 1,582.87% 411.65%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 55.10% 201.15% 185.71%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 308.67% 2,011.23% 852.46%
Earnings before Interest and Taxes (EBIT)
-9.34 -8.58 -11 -11 -10 -11 -8.79 -8.44 -9.02 -32 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.29 -8.53 -11 -11 -9.98 -11 -8.75 -8.38 -8.46 -30 -9.97
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.42 1.80 1.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.25
Price to Tangible Book Value (P/TBV)
1.59 2.04 1.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.29
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.34
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.55 1.94 1.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.15
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.33
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.01 0.08
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.08
Financial Leverage
-0.31 -0.24 -0.28 0.44 -0.14 -0.08 0.51 1.31 -0.04 -0.02 0.67
Leverage Ratio
1.12 1.13 1.12 1.33 1.41 1.48 1.46 1.63 1.61 1.91 1.88
Compound Leverage Factor
1.09 1.11 1.10 1.32 1.41 1.48 1.49 1.64 1.63 1.69 1.90
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 1.22% 1.46% 2.18% 1.77% 0.91% 7.79%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.46% 1.26% 1.05% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 1.22% 0.00% 0.91% 0.72% 0.91% 7.79%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.70% 0.75% 0.70% 5.43% 5.09% 4.53% 3.65% 12.59% 14.20% 10.82% 11.29%
Common Equity to Total Capital
99.30% 99.25% 99.30% 94.57% 94.91% 94.25% 94.89% 85.23% 84.03% 88.27% 80.92%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 -0.05 -0.05 -0.01 -0.11
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 0.12 0.07 0.16 0.07 0.19
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 0.00 -0.02 -0.02 -0.01 -0.11
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.03 -0.03 -0.06 -0.06 -0.02 -0.15
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.03 0.18 0.09 0.23 0.10 0.25
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.03 0.00 -0.03 -0.03 -0.02 -0.15
Altman Z-Score
3.47 5.11 2.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.87
Noncontrolling Interest Sharing Ratio
0.64% 0.70% 0.65% 2.79% 2.67% 2.45% 2.02% 9.23% 10.48% 7.88% 8.22%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.06 5.17 6.75 0.40 0.41 0.37 0.47 0.62 0.99 0.58 0.84
Quick Ratio
3.65 3.01 4.31 0.09 0.02 0.00 0.12 0.09 0.31 0.10 0.34
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-7.38 -12 -11 -116 -9.86 -4.81 -102 -10 -26 -23 82
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -594.65 0.00 -166.66 -706.35 352.77
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -31.39 0.00 -83.64 -39.36 -37.45
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -31.39 0.00 -83.64 -39.36 -37.45
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.04 0.05
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.06 0.08
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.12 0.18
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8,605.10 6,332.06 4,515.65
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,251.55 3,072.23 2,055.42
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,353.55 3,259.83 2,460.23
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
65 67 68 173 68 64 165 177 87 65 75
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.09 0.06
Increase / (Decrease) in Invested Capital
0.84 4.67 3.35 108 2.83 -3.07 96 4.13 20 0.79 -90
Enterprise Value (EV)
100 131 76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15
Market Capitalization
120 143 93 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17
Book Value per Share
$13.33 $0.50 $12.32 $10.42 $8.73 $7.07 $5.91 $6.10 $3.72 $2.75 $2.43
Tangible Book Value per Share
$11.86 $0.44 $10.98 $9.03 $7.48 $5.98 $5.06 $5.26 ($1.01) ($1.71) $2.09
Total Capital
85 80 86 74 69 64 69 79 95 70 82
Total Debt
0.00 0.00 0.00 0.00 0.00 0.79 1.00 1.72 1.68 0.64 6.41
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.79 0.00 0.72 0.68 0.64 6.41
Net Debt
-20 -13 -18 -3.25 -1.10 0.76 -5.09 -2.53 -6.04 -3.95 -11
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2.29 4.84 5.94 -25 -28 -32 -32 -20 -6.98 -28 -25
Debt-free Net Working Capital (DFNWC)
23 17 24 -22 -26 -32 -26 -16 0.74 -23 -8.32
Net Working Capital (NWC)
23 17 24 -22 -26 -32 -27 -17 -0.26 -23 -8.32
Net Nonoperating Expense (NNE)
2.69 0.87 3.13 3.34 3.25 3.63 3.05 2.84 3.08 5.57 3.71
Net Nonoperating Obligations (NNO)
-20 -13 -18 99 -1.10 0.76 97 100 -6.04 -3.95 -1.21
Total Depreciation and Amortization (D&A)
0.05 0.05 0.05 0.05 0.05 0.06 0.04 0.06 0.56 1.76 1.94
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -177.06% -497.56% -356.44%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.71% -415.76% -117.07%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.64% -415.76% -117.07%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($1.50) ($1.25) ($1.50) ($42.75) ($1.30) ($1.27) ($0.80) ($0.72) ($0.38) ($0.95) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding
6.36M 6.36M 6.95M 269.08K 7.49M 8.58M 11.01M 11.07M 21.50M 22.38M 26.17M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($42.75) ($1.30) ($1.27) ($0.80) ($0.72) ($0.38) ($0.95) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 269.08K 7.49M 8.58M 11.01M 11.07M 21.50M 22.38M 26.17M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($42.75) $0.00 $0.00 $0.00 ($0.72) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-4.40 -5.52 -5.30 -5.89 -5.26 -5.99 -4.25 -3.88 -3.32 -20 -5.54
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -84.11% -1,192.62% -371.20%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -231.48% -1,699.81% -805.11%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -51.02 0.00 -57.99 -974.68 -51.40
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -35.71 0.00 -40.59 -682.28 -35.44
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -51.02 0.00 -57.99 -974.68 -51.40
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -35.71 0.00 -40.59 -682.28 -35.44
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% -9.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -9.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Citius Pharmaceuticals (NASDAQ: CTXR) remains in a development and commercialization transition. The company reported its first meaningful operating revenue in the supplied periods during fiscal 2026, but it continues to generate substantial operating losses and negative operating cash flow.

Revenue is emerging, although it has not yet produced profitability. Revenue was $3.9 million in Q1 2026, $1.7 million in Q2 and $1.5 million in Q3. Revenue declined for the second consecutive quarter, but the latest quarter still produced a $1.0 million gross profit and an approximate 67% gross margin. This represents a significant improvement from the zero revenue reported in the comparable 2024 and 2025 periods.

Operating expenses fell sharply to $12.7 million in Q3 2026 from $33.5 million in Q2, primarily because selling, general and administrative expense dropped from $26.4 million to $6.1 million. As a result, the net loss narrowed to $11.9 million from $28.1 million in Q2. However, the company still reported a $8.9 million loss attributable to common shareholders, or $0.34 per share.

Cash resources improved during the latest quarter, but primarily through financing rather than operations. CTXR ended Q3 2026 with $17.0 million of cash, up from $4.6 million at the end of Q2. Financing activities provided $23.1 million in Q3, including common equity issuance and other financing proceeds, while operating activities consumed $8.7 million. The company has reported negative operating cash flow in every supplied quarter, indicating that its commercial operations have not yet become self-funding.

  • Revenue commercialization has begun: CTXR generated $1.5 million of revenue in Q3 2026 after reporting no revenue in the comparable 2024 and 2025 periods.
  • Gross profitability is positive: Q3 gross profit was $1.0 million, with an approximate 67% gross margin despite revenue declining from the prior quarter.
  • Quarterly losses improved materially: The consolidated net loss narrowed to $11.9 million in Q3 from $28.1 million in Q2, while the loss attributable to common shareholders declined to $8.9 million from $21.2 million.
  • Cash reserves recovered: Cash increased to $17.0 million at June 30, 2026, compared with $4.6 million at March 31, 2026 and only $26,000 at March 31, 2025.
  • Debt levels are manageable in absolute terms: CTXR reported no short-term debt and approximately $6.4 million of long-term debt at the end of Q3 2026.
  • Operating expenses remain volatile: The sharp Q3 reduction in SG&A helped results, but the large Q2 expense spike suggests that quarterly earnings may continue to be affected by irregular corporate and special charges.
  • Asset values are concentrated in noncurrent assets: Goodwill and other noncurrent operating assets represented more than $108 million of the $142.3 million asset base, which may limit balance-sheet flexibility if those assets require impairment.
  • Operating cash flow remains negative: CTXR used $8.7 million of cash in operations in Q3 and approximately $23.0 million during the first three quarters of fiscal 2026.
  • The company remains consistently unprofitable: Quarterly net losses have persisted throughout the supplied periods, and retained earnings were negative $277.1 million at June 30, 2026.
  • Funding has required substantial equity issuance: Common equity issuance and other financing supplied much of the cash improvement, while weighted-average shares outstanding rose from 11.1 million in Q4 2025 to 26.2 million in Q3 2026, creating significant dilution risk.

Overall, CTXR’s statements show early revenue generation, improving Q3 expenses and a stronger cash balance. Nevertheless, the investment case remains dependent on sustained revenue growth, better operating cash flow and reduced reliance on additional equity financing. Until those trends develop, the company’s persistent losses, negative cash flow and shareholder dilution remain significant risks for investors.

11/17/26 08:37 PM ETAI Generated. May Contain Errors.

Citius Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Citius Pharmaceuticals' financial year ends in September. Their financial year 2025 ended on September 30, 2025.

Citius Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$39.74 million in 2025, falling from -$2.90 million in 2015. The previous period was -$39.43 million in 2024. See Citius Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Citius Pharmaceuticals' total operating income in 2025 was -$38.53 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $38.53 million

Over the last 10 years, Citius Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, Citius Pharmaceuticals' cash and equivalents has ranged from $26.41 thousand in Q2 2025 to $20.35 million in Q1 2024, and is currently $17.01 million as of their latest financial filing in Q3 2026.

Citius Pharmaceuticals had total debt of $1.72 million at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Citius Pharmaceuticals' book value per share changed from -0.02 in 2015 to 6.10 in 2025.



Financial statements for NASDAQ:CTXR last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners